Remove Heart Valves Remove Hospital Remove Open-Heart Surgery
article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 On average, noted Abbott, people who receive TriClip only need one day in the hospital before they recover and can return home. Abbott has announced U.S million people in the U.S.

Tricuspid 105
article thumbnail

Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

DAIC

It is one of only two New Jersey hospitals offering the trial to patients. Many patients with symptoms of mitral regurgitation are not candidates for open heart surgery due to their advanced age or competing comorbidities, nor are they candidates for the only alternative, the MitraClip device.

article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

article thumbnail

Henry Ford Health Cardiologists Publish Case Series Study on Heart Valve Procedure

DAIC

a Structural Heart Disease Fellow at Henry Ford Hospital, is also optimistic that these findings will lead to helping more people. Patients with severely calcified mitral stenosis are often not candidates for conventional open-heart surgery,” said Dr. Giustino.

article thumbnail

Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

DAIC

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. She is only the third patient in the U.S. to receive the device.

article thumbnail

Minimally Invasive Options For High-Risk Heart Surgery

MIBHS

Known as an alternative to open heart surgery, minimally invasive surgery is preferred by many patients. It involves tiny incisions that allow a surgeon to access the heart between the rib bones. It also allows for less blood loss, reduced pain, shorter hospital stays, and a lower chance of infection.

article thumbnail

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

DAIC

The Medtronic Evolut TAVR platform includes devices less invasive than traditional open-heart surgery for the treatment of symptomatic severe aortic stenosis. “At At Medtronic, we continue to emphasize that valve design matters. Francis Hospital , and faculty member at Columbia University. mmHg TAVR; 11.8

TAVR 52